{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:41Z","timestamp":1791924761388,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40268-019-00288-x","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T21:01:37Z","timestamp":1573765297000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A Clinician\u2019s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis"],"prefix":"10.1007","volume":"19","author":[{"given":"Gaurav","family":"Agnihotri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-0152","authenticated-orcid":false,"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"issue":"14","key":"288_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMra074081","volume":"358","author":"T Bieber","year":"2008","unstructured":"Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483\u201394.","journal-title":"N Engl J Med."},{"issue":"5","key":"288_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jdv.13599","volume":"30","author":"A Wollenberg","year":"2016","unstructured":"Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD\/ EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729\u201347.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"10023","key":"288_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet."},{"key":"288_CR4","unstructured":"Regeneron Pharmaceuticals. Dupixent (dupilumab) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf. Accessed 30 June 2019."},{"issue":"24","key":"288_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med."},{"issue":"10086","key":"288_CR6","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet."},{"issue":"5","key":"288_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M De Bruin-Weller","year":"2018","unstructured":"De Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork M, Radin A, et al. Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol."},{"key":"288_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869","author":"BO Akinlade","year":"2019","unstructured":"Akinlade BO, Guttman-Yassky EM, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.17869.","journal-title":"Br J Dermatol."},{"issue":"10013","key":"288_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Thaci","year":"2016","unstructured":"Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40\u201352.","journal-title":"Lancet."},{"key":"288_CR10","doi-asserted-by":"crossref","unstructured":"Worm M, Simpson EL, Thaci D et al. The effect of dose regimen adjustment on maintenance of clinical response and safety of dupilumab in patients with atopic dermatitis (LIBERTY AD SOLO-CONTINUE). Presented at the 37th annual congress of the European Academy of Allergy and Clinical Immunology (EAACI), Munich, 26\u201330 May 2018.","DOI":"10.26226\/morressier.5afac50ad0241f0023cc9a79"},{"issue":"10","key":"288_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208\u201311.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"288_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280\u20136.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"288_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bjo.82.1.82","volume":"82","author":"E Uchio","year":"1998","unstructured":"Uchio E, Miyakawa K, Ikezawa Z, Ohno S. Systemic and local immunological features of atopic dermatitis patients with ocular complications. Br J Ophthalmol. 1998;82(1):82\u20137.","journal-title":"Br J Ophthalmol."},{"issue":"10039","key":"288_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31\u201344.","journal-title":"Lancet."},{"issue":"26","key":"288_CR15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med."},{"key":"288_CR16","first-page":"A7712","volume":"197","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Zhu H, et al. Dupilumab in patients with corticosteroid-dependent severe asthma: efficacy and safety results from the randomized, double-blind, placebo-controlled phase 3 LIBERTY ASTHMA VENTURE study. Am J Respir Crit Care Med. 2018;197:A7712.","journal-title":"Am J Respir Crit Care Med."},{"issue":"5","key":"288_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA."},{"key":"288_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1177\/2397847317743186","volume":"5","author":"I Hirano","year":"2017","unstructured":"Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M. Dupilumab efficacy and safety in adult patients with active eosinophilic oesophagitis: a randomized double-blind placebo-controlled phase 2 trial. United Eur Gastroenterol J. 2017;5:1138\u201350.","journal-title":"United Eur Gastroenterol J."},{"issue":"5","key":"288_CR19","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.16330","volume":"178","author":"J Thyssen","year":"2018","unstructured":"Thyssen J. Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Br J Dermatol. 2018;178(5):1220.","journal-title":"Br J Dermatol."},{"issue":"11","key":"288_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMc1700366","volume":"376","author":"M Mennini","year":"2017","unstructured":"Mennini M, Dahdah L, Fiocchi A, Simpson EL. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090\u20131.","journal-title":"N Engl J Med."},{"issue":"5","key":"288_CR21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"DS Bakker","year":"2019","unstructured":"Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248\u20139.","journal-title":"Br J Dermatol."},{"issue":"5","key":"288_CR22","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegr\u00e4ber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778\u201380.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"3","key":"288_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","volume":"8","author":"A Maudinet","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8(3):485\u201390.","journal-title":"Ophthalmol Ther."},{"issue":"4","key":"288_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2340\/00015555-3121","volume":"99","author":"LU Ivert","year":"2019","unstructured":"Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99(4):375\u20138.","journal-title":"Acta Derm Venereol."},{"key":"288_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1533567","author":"E Shen","year":"2018","unstructured":"Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-induced follicular conjunctivitis. Ocular Immunol Inflamm. 2018. https:\/\/doi.org\/10.1080\/09273948.2018.1533567.","journal-title":"Ocular Immunol Inflamm."},{"key":"288_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","volume":"7","author":"AC Barnes","year":"2017","unstructured":"Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120\u20132.","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"12","key":"288_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154(12):1485\u20136.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"288_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1203475417743233","volume":"22","author":"M Gooderham","year":"2018","unstructured":"Gooderham M, McDonald J, Papp K. Diagnosis and management of conjunctivitis for the dermatologist. J Cutan Med Surg. 2018;22(2):200\u20136.","journal-title":"J Cutan Med Surg."},{"issue":"16","key":"288_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jama.2013.280318","volume":"310","author":"AA Azari","year":"2013","unstructured":"Azari AA, Barney BP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721\u20139.","journal-title":"JAMA."},{"issue":"3","key":"288_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","volume":"68","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Ishida W, Kishimoto T, Fukushima A. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int. 2019;68(3):383\u20134.","journal-title":"Allergol Int."},{"issue":"7","key":"288_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.15608","volume":"33","author":"JP Thyssen","year":"2019","unstructured":"Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2014international eczema council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224\u201331.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"288_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40257-019-00465-3","volume":"20","author":"Kristen M. Beck","year":"2019","unstructured":"Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part II: Ocular disease secondary to treatments. Am J Clin Dermatol. 2019. https:\/\/doi.org\/10.1007\/s40257-019-00465-3.","journal-title":"American Journal of Clinical Dermatology"},{"issue":"1","key":"288_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","volume":"5","author":"MJ Zirwas","year":"2019","unstructured":"Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep. 2019;5(1):34\u20136.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"288_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jaip.2018.10.055","volume":"7","author":"MJ Rial","year":"2019","unstructured":"Rial MJ, Barroso B, Rodriguez-Bermejo C, Sastre J. Letter regarding \u201cConjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2014clinical characteristics and treatment\u201d. J Allergy Clin Immunol Pract. 2019;7(2):753.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"288_CR35","first-page":"488","volume":"17","author":"N Aszodi","year":"2019","unstructured":"Aszodi N, Thurau S, Seegraber M, de Bruin-Weller M, Wollenberg A. Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges. 2019;17(5):488\u201391.","journal-title":"J Dtsch Dermatol Ges."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-00288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-019-00288-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-00288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:27:58Z","timestamp":1605227278000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-019-00288-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-00288-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"14 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Gaurav Agnihotri and Katherine Shi have no conflicts of interest that are directly relevant to the content of this article. Peter A. Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme\/Regeneron.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}